RxDoctor Payments Data

Ellen Ginzler, MD

Rheumatology · Brooklyn, NYNPI 1952395618

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,359 of the $32,481 with a category attached, or 75.0%. 10 manufacturers reported payments, led by GSK at 55.1% of the total. Reporting peaked in 2019 at $14,728 and has fallen 98.5% since, to $225 in 2025.

$32,481in general payments, 2019–2025

Across 79 payments — averaging $411.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$18K
  • AstraZeneca$7K
  • Johnson & Johnson$5K
  • Aurinia Pharma U.S., Inc.$3K
  • Boehringer Ingelheim$142
  • Lilly USA, LLC$113
  • plus $229 from 4 others
$170,672in research payments, 2019–2025

Across 36 payments — averaging $4740.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$62K
  • Genentech, Inc.$51K
  • AbbVie$30K
  • GSK$16K
  • Aurinia Pharma U.S., Inc.$13K

What the payments were for

  • Consulting fees$24,35975%
  • Travel & lodging$5,68217%
  • Food & beverage$2,2807%
  • Education$1600%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,481 in reported general payments places this provider in the 85th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York →

Medicare billing

Part B allowed, 2024
$4,284
Medicare patients
28
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Brooklyn

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →